Panic-related responses to pentagastrin, flumazenil, and thyrotropin-releasing hormone in healthy volunteers

Depression and Anxiety

Volumn 17, Issue 2, 2003, Pages 78-87

  Zedkova, Lenka ^a,b   Coupland, Nicholas J ^a   Man, Godfrey C W ^a   Dinsa, Gurpreet ^a   Sanghera, Gurinder ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cognitive models; Panic attacks; Panic disorder; Pharmacological challenge

Indexed keywords

FLUMAZENIL; PENTAGASTRIN; PROTIRELIN;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; GABAERGIC SYSTEM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; VOLUNTEER;

ADULT; AROUSAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUMAZENIL; HUMANS; MALE; PANIC; PENTAGASTRIN; THYROTROPIN-RELEASING HORMONE;

EID: 0037252417     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10085     Document Type: Article

References (51)

1. Abelson JL, Nesse RM. 1994a. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol Psychiatry 36:73-83.]
2. Abelson JL, Nesse RM, Vinik AI. 1994b. Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology. Biol Psychiatry 36:84-96.
3. Abelson JL, Nesse RM, Weg JG, Curtis GC. 1996. Respiratory psychophysiology and anxiety: cognitive intervention in the doxopram model of panic. Psychosom Med 58:302-313.
4. Barlow DH, Lehman CL. 1996. Advances in the psychosocial treatment of anxiety disorders. Arch Gen Psychiatry 53:727-735.
5. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
6. Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, Rich A, Nutt DJ. 2002. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16:5-14.
7. Borg GAV. 1982. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 14:337-381.
8. Bouloux P-M, Corsello S, Besser M, Grossman A. 1996. The acute cardiovascular actions of intravenous thyrotrophin releasing hormone (TRH) in man are mediated by non-catecholaminergic mechanisms. Br J Clin Pharmacol 42:225-232.
9. Bourin M, Baker GB, Bradwejn J. 1998. Neurobiology of panic disorder. J Psychosom Res 44:163-180.
10. Bradwejn J, Koszycki D, Shriqui C. 1991. Enhanced sensitivity to cholecystokinin-tetrapeptide in PD: clinical and behavioral findings. Arch Gen Psychiatry 48:603-607.
11. Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S, Karkanias C. 1992a. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in PD. Biol Psychiatry 32:903-912.
12. Bradwejn J, Koszycki D, Payeur R, Bourin M, Borthwick H. 1992b. Study of the replication of action of cholecystokinin in panic disorder. Am J Psychiatry 149:962-964.
13. Bradwejn J. 1993. Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatr Neurosci 18:178-188.
14. Carter MM, Hollon SD, Carson R, Shelton RC. 1995. Effects of a safe person on induced distress following a biological challenge in panic disorder with agoraphobia. J Abnormal Psychol 104: 156-163.
15. Chambless DL, Caputo GC, Bright P, Gallagher R. 1984. Assessment of fear in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 52:1090-1097.
16. Clark DM. 1986. A cognitive approach to panic. Behav Res Ther 24:461-470.
17. Coupland NJ, Bailey JE, Glue P, Nutt DJ. 1995. The cardiovascular and subjective effects of thyrotropin releasing hormone (TRH) and a stable analogue, dimethylproline-TRH, in healthy volunteers. Br J Clin Pharmacol 40:223-229.
18. Darragh A, Lambe R, Kenny M, Brick, I. 1983. Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788. Eur J Clin Pharmacol 24: 569-570.
19. First MB, Spitzer RL, Gibbon M, Williams JRW. 1997. Structural clinical interview for DSM-IV axis I disorders. Washington DC: Am Psych Press, Inc.
20. Garbutt JC, Mayo JP, Little KY, Gillette GM, Mason GA, Dew B, Prange AJ, Jr. 1994. Dose-response studies with protirelin. Arch Gen Psychiatry 51:875-883.
21. Harrison WM, Sandberg D, Gorman JM, Fyer M, Nee J, Uy J, Endicott J. 1989. Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. Psychiatr Res 27:183-192.
22. Higgitt A, Lader M, Fonagy P. 1986. The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects. Psychopharmacology 89:395-403.
23. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. 1990. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87: 6728-6732.
24. Koszycki D, Zacharko RM, Bradwejn J. Influence of personality on behavioral response to CCK-4 in patients with panic disorder. Psychiatry Res 62:131-138.
25. Le Mellédo J-M, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, Steinberg S, Bichet DG, Bradwejn J. 1999. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology 20:81-91.
26. Margraf J, Ehlers A, Roth WT. 1989. Expectancy effects and hyperventilation as laboratory stressors. In: Weiner H, Florin I, Murrison R, Hellhammer D, editors. Frontiers of stress research. Toronto: Huber.
27. Marks IM, Mathews AM. 1979. Brief standard self-rating for phobia patients. Behav Res Ther 17:263-267.
28. McCann UD, Slate SO, Geraci M, Uhde TW. 1994/1995. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers. Anxiety 1:258-267.
29. Merchenthaler I, Csernus V, Csontons C, Petrusz P, Mess B. 1988. New data on the immunocytochemical location of thyrotropin-releasing hormone in the rat central nervous system. Am J Neuroanat 181: 359-376.
30. Morley JE. 1979. Extrahypothalamic thyrotropin-releasing hormone (TRH): its distribution and its function. Life Sci 25:1539-1550.
31. Nutt DJ, Glue P, Lawson C, Wilson S. 1990. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 47:917-925.
32. Nutt DJ, Lawson C. 1992. Panic attacks: A neurochemical overview of models and mechanisms. Br J Psychiatry 160:165-178.
33. Papp LA, Welkowitz LA, Martinez JM, Klein DF, Browne S, Gorman JM. 1995. Instructional set does not alter outcome of respiratory challenge in panic disorder. Biol Psychiatry 38:826-830.
34. 2 in panic patients. Biol Psychiatry 37:528-532.
35. Rapee RM, Mattick R, Murrell E. 1986. Cognitive mediation in the affective component of spontaneous panic attacks. J Behav Ther Exp Psychiatry 17:243-253.
36. 2 in agoraphobics. Behav Res Ther 29:353-355.
37. Rapee RM, Brown TA, Anthony MA, Barlow DH. 1992. Response to hyperventilation and inhalation of 5.5% carbon dioxide-enriched air across the DSM-III-R anxiety disorders. J Abnormal Psychol 101:538-552.
38. Rapee RM. 1993. Psychological factors in panic disorder. Adv Behav Res Ther 15:85-102.
39. Reiss S, Peterson RA, Gursky DM, McNally RJ. 1986. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther 24:1-8.
40. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. 1990. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 47:534-538.
41. Roy-Byrne PP, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS. 1996. Reduced benzodiazepine sensitivity in panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatry 153: 1444-1449.
42. Sanderson WC, Rapee RM, Barlow DH. 1989. The influence of an illusion of control on panic attacks induced via inhalation of 5.5% of carbon dioxide-enriched air. Arch Gen Psychiatry 46:157-162.
43. Schöpf J, Laurian S, Le PK, Gaillard, J-M. 1984. Intrinsic activity of the benzodiazepine antagonist Ro 15-1788 in man: an electrophysiological investigation. Pharmacopsychiatry 17:79-83.
44. Stein MB, Uhde TW. 1990. Thyrotropin and prolactin responses to protirelin (TRH) prior to and during chronic imipramine treatment in patients with panic disorder. Psychoneuroendocrinology 15:381-389.
45. Stein MB, Uhde TW. 1991. Endocrine, cardiovascular and behavioral effects of intravenous protirelin in patients with panic disorder. Arch Gen Psychiatry 48:148-156.
46. Ströhle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K. 1998. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155:610-612.
47. Ströhle A, Kellner M, Holsboer F. Wiedemann K. 1999. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry 45:321-326.
48. Tancer ME, Murray MB, Uhde TW. 1990. Paradoxical growth-hormone responses to thyrotropin-releasing hormone in panic disorder. Biol Psychiatry 27:1227-1230.
49. van Megen HJ, Westenberg HG, den Boer JA, Haigh JR, Traub M. 1994. Pentagastrin-induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacol 114: 449-455.
50. Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. 1991. Behavioral, biochemical and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 36: 115-127.
51. Zedkova L, Man GCW, Coupland NJ. 2001. Serum cortisol and flumazenil-induced panic (abstract). Proceedings of the 24th Canadian College of Neuropsychopharmacology annual meeting, June 17-20, Banff, p 39.